Advanced Endoscopic Technologies Market : Global Industry Analysis and Opportunity Assessment, 2036

How big is Advanced Endoscopic Technologies Market in 2026?

USD 1,118.9 million in 2026 and USD 2,822.3 million by 2036 at a 9.7% CAGR.

Demand for advanced endoscopic technologies is anticipated to expand at 9.7% CAGR between 2026 and 2036, increasing valuation from USD 1,118.9 million in 2026 to USD 2,822.3 million by 2036. Hospital groups purchase scopes and processors through capital plans that also cover reprocessing and service support. The Centers for Disease Control and Prevention reported in August 2025 that 53.4% of United States adults aged 45 to 75 had used colonoscopy within ten years. The national procedure base creates recurring room-capacity and platform-availability requirements without determining purchase timing by itself. Current flexible endoscopes support diagnostic access across gastrointestinal and pulmonary pathways through reusable and single-use configurations. Connected endoscopy video systems add image enhancement and documentation functions that influence processor replacement decisions. Hospital committees therefore compare clinical image quality with scope compatibility and repair turnaround during every platform evaluation.

United States providers use mixed hospital and ambulatory purchasing routes that reward measurable procedure capacity. British providers face public waiting-list pressure and assess systems through service impact across scheduled diagnostic programs. Japanese institutions emphasize durable performance and disciplined maintenance during longer replacement cycles across experienced clinical teams. South Korean screening networks create dense workloads that support rapid evaluation of imaging and interpretation tools. Each route changes the preferred balance between reusable systems and disposable endoscopes across different clinical settings. Specialized capsule endoscopy systems extend visualization into anatomy that conventional scopes may not examine directly. Local reimbursement and maintenance coverage therefore determine whether clinical interest becomes a repeatable purchasing program across each provider network.

Summary of the Advanced Endoscopic Technologies Market

Market Signal	Commercial Impact
Demand and Growth Drivers	Hospitals often invest in advanced endoscopy when clinical workloads require dependable visualization and consistent procedure capacity across several departments. Cancer screening and surveillance create recurring examination workloads that justify replacement planning for scopes and processors. Therapeutic procedures add accessory and imaging requirements that extend spending beyond diagnostic visualization equipment alone. Service response and reprocessing capacity influence usable equipment availability during tightly scheduled clinical operating periods.
Product and Segment View	The product architecture combines scopes with processors and software that support diagnostic review or minimally invasive treatment. Endoscopes are estimated to hold 40.6% of product type revenue in 2026 owing to their direct procedural role. Gastroenterology is projected to represent 25.6% share in 2026 due to broad diagnostic and therapeutic use. Hospitals are expected to account for 33.4% of end user revenue owing to multi-department capital purchasing. High-definition imaging improves visual detail but creates compatibility and training requirements across existing equipment inventories.
Geography and Growth Outlook	National adoption differs through screening routes and provider financing alongside local service access and equipment regulation. South Korea is forecast at 11.8% CAGR through 2036, due to dense screening networks and rapid clinical technology evaluation. By 2036, Germany is projected at 9.5% CAGR within an organized screening environment and formal purchasing review. Japan is estimated at 8.7% CAGR due to established clinical expertise and disciplined equipment replacement across hospital networks. United States and United Kingdom growth depends on capacity economics and dependable maintenance across different purchasing systems.
Competitive Landscape	Competition separates complete visualization platforms from therapeutic specialists and robotic systems that address narrower clinical procedures. Olympus and Fujifilm provide gastrointestinal imaging platforms that connect scopes with processors and software functions. PENTAX Medical competes through processor compatibility and flexible scope options for recurring gastrointestinal examination workflows across healthcare facilities. KARL STORZ and Stryker emphasize surgical visualization with operating-room integration across several procedural specialties and hospital departments. Boston Scientific and Medtronic focus on therapeutic products and digitally assisted gastrointestinal procedure support across diagnostic and treatment pathways.
Analyst Perspective	Clinical value depends on whether improved visualization produces dependable decisions without increasing procedure complexity or equipment downtime. Hospital committees should compare image performance with reprocessing capacity and service response across representative workloads. Department leaders need to measure procedure completion and interpretation consistency as separate evaluation outcomes during trials. Contracts should define software updates and equipment compatibility alongside repair obligations across the expected platform life. - Anurag Sharma, Principal Analyst at Future Market Insights

Source: FMI’s proprietary forecasting model and primary research

How is the advanced endoscopic technologies market segmented?

The advanced endoscopic technologies industry is segmented by product type, application, end user, technology, and region.

The segmentation framework separates physical equipment from clinical purpose and purchasing setting inside the defined revenue boundary. Product type distinguishes endoscopes from visualization systems and ultrasound platforms alongside accessories and capsule solutions. Application analysis follows gastroenterology and pulmonology together with urology and surgery across distinct clinical procedure pathways. End user categories distinguish hospitals from ambulatory centers and specialty clinics with different capital approval routes. Technology analysis separates high-definition imaging from narrow-band and ultrasound methods alongside robotic or capsule-based systems. Regional analysis evaluates regulation and clinical infrastructure together with service access across national healthcare systems.

What makes Endoscopes central to the Product Type category?

Endoscopes provide the physical route for visualization and instrument access across diagnostic or therapeutic procedures. Scope design determines reach and working-channel capacity alongside maneuverability and image transmission during each examination. Reusable platforms support repeated clinical use but require validated cleaning and dependable repair services throughout scheduled operating periods. Single-use models avoid reprocessing between cases yet create recurring unit costs and disposal requirements for every completed procedure. Investment in endoscope reprocessing devices therefore influences operating economics and daily availability across reusable equipment inventories.

• By product type, endoscopes are estimated to hold 40.6% share in 2026 owing to their direct role during visual examination and instrument delivery. The position reflects recurring purchases and replacements across reusable and single-use configurations rather than processor spending alone.
• Hospital endoscopy units favor scopes that fit existing processors and accessory inventories without disrupting scheduled procedures. PENTAX Medical announced in December 2024 that two i20c video endoscope models and one reusable wheel extender received United States FDA clearance. The clearance gives gastrointestinal departments another compatible replacement route with defined ergonomic support for recurring examinations.

Why does Gastroenterology shape demand within the Application category?

Gastroenterology combines screening volume with interventions that require stable visualization and accessory control throughout each procedure. Colonoscopy and upper gastrointestinal examinations use processors across diagnostic and treatment pathways during recurring daily schedules. FUJIFILM Healthcare Americas Corporation reported in March 2024 that CAD EYE received United States clearance for real-time colonic lesion detection. The clearance connects imaging equipment with software support during routine colonoscopy review across compatible United States facilities. Complex procedures also require compatible scopes and ultrasound accessories for tissue sampling and therapeutic planning.

• Gastroenterology is projected to represent 25.6% of application revenue in 2026 supported by its broad procedure range and recurring replacement needs. The position also reflects processor demand across diagnostic imaging and therapeutic accessory use inside the same clinical department throughout scheduled procedures.
• Gastrointestinal units adopt advanced platforms when physicians can use enhanced imaging without extending routine procedure time. Specialized ERCP devices add treatment pathways that differ from standard visual diagnosis and require compatible imaging support. Platform selection must preserve accessory compatibility and documented image capture through every procedural step inside the gastroenterology department.

How do Hospitals influence purchasing within the End User category?

Hospitals operate several endoscopy rooms and often share visualization platforms across clinical specialties inside one healthcare facility. Capital committees consider processor utilization and scope inventories alongside maintenance contracts and staff training across several clinical departments. Emergency coverage also matters as equipment availability extends beyond scheduled outpatient lists and supports urgent inpatient procedures. Large institutions can spread platform cost across gastroenterology and surgery together with pulmonology and urology. Purchasing decisions therefore require a complete view of service exposure and cross-department compatibility across the entire healthcare facility.

• Based on end user, hospitals are expected to account for 33.4% share in 2026 underpinned by concentrated procedure capacity and multi-department purchasing. Their position reflects investment in complete systems that combine processors and scopes with accessories and ongoing technical support across several clinical departments.
• Hospital adoption improves through shared platforms that reduce separate maintenance routes across several clinical departments and procedure rooms. FUJIFILM Healthcare Americas Corporation announced in June 2026 that its new United States endoscopy warehouse supports a service-center expansion to approximately 1.5 times the former size. Similar planning across gastroenterology and ENT endoscopy requires documented service response for each installed platform.

What supports High-definition Endoscopy within the Technology category?

High-definition endoscopy increases image detail during lesion inspection and therapeutic navigation across several clinical specialties. Resolution creates clinical value through monitors and processors that preserve the complete image chain during every examination. Phased upgrades require compatibility across scope generations and installed processors throughout the complete equipment replacement period. Departments also need interpretation protocols that separate meaningful clinical findings from additional visual complexity during routine procedures. The technology therefore competes through measurable system performance rather than resolution labels presented without clinical workflow evidence.

• High-definition endoscopy is projected to hold 34.3% share in 2026 attributable to broad compatibility with routine procedures. Olympus announced in May 2025 that its EZ1500 endoscopes received United States clearance for extended-depth-of-field imaging within the EVIS X1 system. The clearance adds a current route for sharper focus across changing examination distances during gastrointestinal procedures.
• Clinical teams adopt high-definition systems through trials that compare lesion visibility and navigation across representative procedures. Compatible AI capsule reading platforms can extend image interpretation beyond conventional rooms through separate review workflows. Purchasing committees should evaluate image detail and interpretation workload as different operating outcomes during representative clinical trials.

What are the drivers, restraints, and opportunities in the advanced endoscopic technologies market?

Screening and therapeutic workloads support investment in advanced imaging, while reprocessing burden constrains usable capacity and connected software creates a verified expansion route.

• Driver: Organized screening and therapeutic procedures create recurring demand for dependable visualization across scheduled clinical programs.
• Restraint: Reusable scope reprocessing requires trained labor and validated steps that can restrict daily equipment availability.
• Opportunity: Cleared imaging software can add decision support to installed endoscopy platforms without replacing every physical component.

Screening eligibility creates recurring examinations that require dependable scopes and processors across organized clinical programs. Equipment spending follows room utilization and replacement planning across facilities that maintain organized screening capacity. The Centers for Disease Control and Prevention reported in August 2025 that 61.4% of United States adults aged 45 to 75 were current with colorectal cancer screening during 2022. The remaining gap supports outreach that can raise workloads across facilities with prepared endoscopy capacity. Investment in endoscopic closure systems also extends equipment use from diagnosis into minimally invasive treatment.

Reusable equipment creates a material operating constraint through cleaning requirements and potential repair downtime across scheduled departments. The USA Food and Drug Administration stated that reprocessing is labor-intensive and time-consuming for healthcare facilities across the United States. Each device requires a specific regimen that includes initial decontamination and thorough cleaning followed by disinfection or sterilization. Hospitals therefore need trained technicians and enough scope inventory to protect procedure capacity during every reprocessing cycle. Adoption slows if a platform upgrade raises cleaning complexity without improving daily availability or service response.

Connected software creates an opening for hospitals that need additional interpretation support without replacing every compatible scope. Olympus reported in September 2024 that its United States subsidiary Odin Medical received FDA clearance for the cloud-based CADDIE polyp-detection system. The clearance establishes a commercial pathway for remotely updated decision support during colonoscopy procedures across compatible hospital systems. Related endoscopic ultrasound needles create a separate opportunity through image-guided tissue acquisition and minimally invasive intervention workflows. Technology providers must prove processor compatibility and secure workflow integration before hospitals expand software across procedure rooms.

Which country CAGRs are profiled in the advanced endoscopic technologies market?

Country	CAGR
USA	7.9%
UK	7.7%
Germany	9.5%
Japan	8.7%
South Korea	11.8%

How do country-level CAGRs compare in the advanced endoscopic technologies market?

The country comparison forms three visible growth bands across the assessment period. South Korea sits apart from the middle group with a forecast rate that reflects rapid clinical technology evaluation and dense screening activity. Germany and Japan form the central band with less than one percentage point separating their forecast rates. The USA and UK create a closely grouped lower band with two-tenths of one percentage point between their values. The complete spread between South Korea and the UK equals 4.1 percentage points across the country comparison.

• The 4.1-point separation describes forecast momentum inside this market and does not establish current national market size.
• South Korea and Germany show a 2.3 percentage-point separation that can affect the timing of distributor investment and specialist training. Japan follows Germany by eight-tenths of one percentage point and remains close enough for service economics to influence comparative entry decisions.
• The USA trails Japan by eight-tenths of one percentage point despite its broad provider base and mixed purchasing routes.
• The UK remains near the USA as public procurement and capacity programs create a different path from private capital replacement.

Similar rates therefore require separate commercial plans rather than one standardized regional launch sequence for every provider system. The country figures show relative development speeds but do not replace direct analysis of regulation and service access. Companies should compare product approval and maintenance coverage together with training routes and facility purchasing structures. A higher CAGR can coexist with a smaller installed base or narrower current sales channel. The full report provides country-level CAGR analysis across North America, Latin America, Europe, East Asia, South Asia, Oceania and the Middle East and Africa.

Country-wise Analysis

• United States healthcare systems combine hospital capital plans with ambulatory purchasing across several endoscopy specialties. Demand for advanced endoscopic technologies in the USA is forecast to rise at 7.9% CAGR by 2036 supported by broad procedure settings and established distribution channels. Olympus announced in September 2025 that its global MacroLux distribution agreement includes the United States for single-use cystoscopes and ureteroscopes. The agreement gives urology departments another commercial route for visualization without adding reusable-scope inventory across every procedure room. Budget pressure and service-contract complexity remain material frictions across multi-site systems with different purchasing priorities. Manufacturers need defined training and repair responsibilities prior to expanding placements beyond initial departments and ambulatory facilities.
• United Kingdom providers operate through publicly funded diagnostic programs that connect equipment investment with waiting-list reduction. Adoption of advanced endoscopic technologies in the UK is estimated to expand at 7.7% CAGR through 2036 supported by national capacity programs. NHS England reported in October 2025 that imaging and endoscopy investments produced 275,000 additional endoscopies during 2024 and 2025. The added activity creates a direct capacity enabler for systems that improve room availability and reporting continuity. Central budget limits and local service performance remain practical frictions across provider trusts with different diagnostic capacity needs. Suppliers need measurable throughput benefits and dependable maintenance routes during public procurement reviews across local provider trusts.
• Germany combines statutory screening access with ambulatory specialists and hospital endoscopy services across regulated purchasing channels. The German advanced endoscopic technologies sector is projected to record 9.5% CAGR during the assessment period supported by broader colorectal screening eligibility. Germany’s Federal Ministry of Health reported in February 2026 that women and men aged 50 can use the same colonoscopy options under rules effective from April 2025. The organized pathway enables predictable examination demand across qualified facilities that participate in statutory colorectal screening programs. Formal evidence review and service documentation can lengthen equipment qualification across hospital and ambulatory provider settings. Market entry requires German-language training and a documented repair route that protects scheduled screening capacity across qualified facilities.
• Japanese endoscopy departments operate with experienced clinical teams and long equipment cycles across hospital networks. Demand for advanced endoscopic technologies in Japan is forecast to rise at 8.7% CAGR over the forecast period, supported by established specialist workflows. Olympus announced in October 2025 that domestic sales of its EVIS X1 CV-1500 processor with combined NBI and TXI observation would begin on November 4. The release gives Japanese providers a current upgrade route for enhanced lesion visualization within a familiar platform architecture. Conservative replacement planning and strict workflow validation can delay broader adoption across hospital departments during staged replacement programs. Manufacturers need local training and maintenance plans that preserve clinical continuity throughout staged processor and scope upgrades.
• South Korean hospitals operate through dense referral networks with strong digital infrastructure and concentrated specialist services. Sales of advanced endoscopic technologies in South Korea are forecast to expand at 11.8% CAGR by 2036 supported by rapid evaluation at tertiary centers. The National Cancer Center Korea reported in May 2025 that it introduced the country’s first ION robotic-assisted bronchoscopy system and planned clinical use from June. The installation provides direct local evidence for advanced navigation during difficult peripheral lung biopsy procedures. Specialist training and service access can remain concentrated outside major urban centers across regional healthcare facilities. Companies need support plans that extend maintenance coverage beyond tertiary hospitals without weakening clinical response times.

Who are the notable companies in the advanced endoscopic technologies market?

Olympus Corporation, FUJIFILM Healthcare Americas Corporation, KARL STORZ, Stryker Corporation, Boston Scientific Corporation, Medtronic plc, PENTAX Medical, and Johnson & Johnson MedTech are the notable companies profiled in this market.

Competition spans complete gastrointestinal imaging platforms and surgical visualization systems alongside therapeutic devices and robotic bronchoscopy. Olympus and Fujifilm connect scopes with processors and imaging software across gastrointestinal workflows. PENTAX Medical provides flexible scopes and processor compatibility that support phased equipment replacement across gastrointestinal procedure rooms. KARL STORZ and Stryker address surgical visualization with operating-room integration across several clinical specialties and procedure settings. Boston Scientific and Medtronic concentrate more heavily on therapeutic endoscopy and digitally assisted procedures across gastrointestinal care pathways. Johnson & Johnson MedTech participates through robotic bronchoscopy with continuous visualization and navigation support for peripheral lung access. Selection therefore depends on verified procedure fit and accountable service ownership rather than corporate scale or reputation.

• Olympus and Fujifilm provide broad gastrointestinal imaging systems that connect scopes with processors and software support. PENTAX Medical offers compatible scope and processor routes that can reduce disruption during phased replacement programs.
• KARL STORZ and Stryker combine surgical visualization with room integration across several procedural specialties and hospital operating environments. Boston Scientific adds therapeutic devices that support minimally invasive intervention through compatible endoscopic working channels during gastrointestinal procedures.
• Medtronic supports gastrointestinal procedures through therapeutic tools and AI-assisted colonoscopy software across diagnostic and treatment workflows. Johnson & Johnson MedTech addresses peripheral lung access through robotic bronchoscopy and AI-assisted navigation technology during biopsy procedures.

Competitive Benchmarking: Advanced Endoscopic Technologies Market

Company	Flexible Endoscopy Platform	Advanced Imaging	Therapeutic or Robotic Integration	Geographic Reach
Olympus Corporation	High	High	High	United States, Europe, and Asia-Pacific
FUJIFILM Healthcare Americas Corporation	High	High	Medium	United States
KARL STORZ	Medium	High	High	United States
Stryker Corporation	Medium	High	High	United States
Boston Scientific Corporation	Medium	Medium	High	United States
Medtronic plc	Medium	High	High	United States and Europe
PENTAX Medical	High	High	Medium	United States
Johnson & Johnson MedTech	Medium	High	High	United States

Flexible Endoscopy Platform receives High for a current scope and processor system and Medium for a procedure-specific visualization route. Advanced Imaging receives High for current HD or 4K imaging with enhancement or AI and Medium for narrower imaging support. Therapeutic or Robotic Integration receives High for broad therapy or robotic integration and Medium for limited therapy support without broad integration. Geographic Reach uses descriptive labels based on official availability information for each verified product portfolio. Low denotes an officially documented limitation within the defined market and unavailable public information is not scored.

Key Developments in the Advanced Endoscopic Technologies Market

• In May 2026, Olympus Corporation introduced the Canon Aplio i800 EUS premium ultrasound system for United States gastroenterology and pulmonary customers through an exclusive distribution arrangement. The launch gives Olympus customers a current ultrasound route for detailed assessment during gastrointestinal and pulmonary procedures.
• In May 2026, FUJIFILM Healthcare Americas Corporation launched the EB-710US balloon-less endobronchial ultrasound bronchoscope in the United States with 180-degree upward angulation and a 5.9-millimeter insertion tube. The design reduces balloon preparation and supports access during pulmonary ultrasound procedures across complex airway examination workflows.
• In February 2026, Medtronic plc received CE Mark approval for ColonPRO as the fourth-generation software for AI-assisted colonoscopy in Europe. The software adds real-time polyp sizing and procedural highlights that can support endoscopist review and surveillance decisions.
• In March 2025, Johnson & Johnson MedTech received United States 510(k) clearance for MONARCH QUEST with AI navigation and a verified OEC Open interface for the GE HealthCare OEC 3D mobile CBCT imaging system. The clearance expands navigation support during robotic bronchoscopy for peripheral lung access and targeted biopsy procedures.

Key Players in the Advanced Endoscopic Technologies Market

Flexible Endoscopy and Imaging Platform Providers

• Olympus Corporation
• FUJIFILM Healthcare Americas Corporation
• PENTAX Medical

Surgical Visualization and Procedure Device Providers

• KARL STORZ
• Stryker Corporation
• Boston Scientific Corporation

Digital and Robotic Endoscopy Providers

• Medtronic plc
• Johnson & Johnson MedTech

Advanced Endoscopic Technologies Market - Report Scope

Coverage field	Report scope
Market breakdown	Product Type, Application, End User, Technology, and Region
Quantitative Units	USD Million
Market Definition	Advanced endoscopic technologies include scopes, visualization systems, ultrasound platforms, capsule systems, accessories, and digital imaging technologies used directly during minimally invasive diagnosis or treatment.
Regions Covered	North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, Middle East and Africa
Countries Covered	USA, UK, Germany, Japan, South Korea, and more than twenty-five additional countries in the full report
Key Companies Profiled	Olympus Corporation, FUJIFILM Healthcare Americas Corporation, KARL STORZ, Stryker Corporation, Boston Scientific Corporation, Medtronic plc, PENTAX Medical, and Johnson & Johnson MedTech
Forecast Period	2026 to 2036
Approach	Hybrid bottom-up and top-down sizing that reconciles product revenues, procedure exposure, replacement cycles, and country adoption conditions.

Advanced Endoscopic Technologies Market - Research Methodology

Method	Approach
Primary Research	FMI analysts gathered input from manufacturers, service providers, technology developers, distributors, end users, procurement teams, and subject-matter experts. Interviews examined purchasing decisions, product or service evaluation, adoption barriers, approval requirements, pricing considerations, and expectations for technical or commercial support. Respondents were also asked what evidence is required before a trial, pilot, or initial order develops into regular purchasing.
Desk Research	Desk research covered government statistics, regulatory publications, trade data, industry associations, technical literature, standards, company filings, product information, and official corporate announcements. Sources were reviewed for relevance, publication date, geographic coverage, and consistency with the defined market scope. Claims relating to performance, applications, approvals, capacity, investment, and commercial activity were retained only when supported by credible public evidence.
Market Sizing and Forecasting	The market model combined the baseline value with historical performance, segment structure, pricing and volume indicators, adoption levels, company participation, and country-level demand conditions. Forecast assumptions considered economic activity, investment trends, regulatory developments, technology adoption, purchasing cycles, supply availability, and barriers to wider market use. Segment and regional estimates were reconciled before the final market total was calculated.
Data Validation	Estimates were checked against multiple independent indicators, including public data, company activity, trade patterns, industry developments, and findings from primary interviews. Validation also tested whether products, services, applications, and company revenues fell within the defined market boundaries. Adjacent categories, unsupported claims, overlapping revenues, and activities without direct market relevance were excluded to reduce double counting and maintain consistency across segments and countries.

Advanced Endoscopic Technologies Market by Segments

Advanced Endoscopic Technologies Market segmented by Product Type:

• Endoscopes
• Visualization Systems
• Endoscopic Ultrasound Systems
• Capsule Endoscopy Systems
• Endotherapy Devices and Accessories

Advanced Endoscopic Technologies Market segmented by Application:

• Gastroenterology
• Pulmonology
• Urology
• Gynecology
• General Surgery
• ENT and Other Applications

Advanced Endoscopic Technologies Market segmented by End User:

• Hospitals
• Ambulatory Surgical Centers
• Specialty Clinics
• Diagnostic Centers
• Other Healthcare Facilities

Advanced Endoscopic Technologies Market segmented by Technology:

• High-definition Endoscopy
• Narrow-band Imaging
• Endoscopic Ultrasound
• Capsule Endoscopy
• Robot-assisted Endoscopy

Advanced Endoscopic Technologies Market by Region:

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• Sabatino, S. A., Thompson, T. D., Croswell, J. M., Villarroel, M. A., Rodriguez, J. L., Adam, E. E., & Richardson, L. C. (2025, August 14). Use of Cancer Screening Tests, United States, 2023.
• King, S. C., King, J., Thomas, C. C., & Richardson, L. C. (2025, August 7). Baseline Estimates of Colorectal Cancer Screening Among Adults Aged 45 to 75 Years, Behavioral Risk Factor Surveillance System, 2022.
• USA Food and Drug Administration (2018, January 12). How are Reusable Medical Devices Reprocessed?
• Olympus Corporation (2024, September 6). First Cloud-Based AI Endoscopy System for Colonoscopy Receives FDA Clearance.
• PENTAX Medical (2024, December 10). PENTAX Medical obtained US FDA 510(k) clearance for new models of the PENTAX Medical i20c Video Endoscope Series.
• FUJIFILM Healthcare Americas Corporation (2024, March 20). Fujifilm Receives 510(k) Clearance for CAD EYE®, New AI-Powered Endoscopic Imaging Technology for Colonic Polyp Detection.
• FUJIFILM Healthcare Americas Corporation (2026, June 17). Fujifilm Opens New Endoscopy Warehouse Facility in Fairfield, NJ, Expanding Service Operations and Supporting Continued Business Growth.
• Olympus Corporation (2025, May 28). Olympus Announces FDA Clearance of Its Most Advanced Imaging Endoscopes.
• Olympus Corporation (2025, September 4). Olympus Announces Distribution Partnership with MacroLux Medical for Single-Use Urology Products.
• NHS England (2025, October 31). Performance Report.
• Federal Ministry of Health (2026, February 13). Weil früher besser ist - die wichtigsten Fragen zur Darmkrebs-Vorsorge.
• Olympus Corporation (2025, October 29). [Olympus Adds an Observation Mode to the EVIS X1 Endoscopy System to Support Improved Lesion Visibility].
• National Cancer Center Korea (2025, May 19).[National Cancer Center Introduces Korea’s First Advanced Robotic Bronchoscopy System for Lung Cancer Diagnosis].
• Olympus Corporation (2026, May 4). Olympus and Canon Introduce the Aplio i800 EUS Premium Ultrasound System in the USA
• FUJIFILM Healthcare Americas Corporation (2026, May 18). Fujifilm Launches the EB-710US, a Novel Next-Generation, Balloon-less Endobronchial Ultrasound (EBUS) Bronchoscope for Pulmonary Care.
• Medtronic plc (2026, February 23). Medtronic Announces CE Mark for the Next Generation GI Genius™ Module and ColonPRO™ Software.
• Johnson & Johnson MedTech (2025, March 12). Johnson & Johnson MedTech Announces Clearance of MONARCH™ QUEST for Enhanced Robotic-Assisted Bronchoscopy.

This bibliography is provided for reader reference and is not exhaustive. The full report contains the complete reference list and detailed citations.

This Report Answers

• How large is the advanced endoscopic technologies market in 2026 and 2036?
• Which clinical workloads support investment in advanced endoscopy equipment and software?
• Why do endoscopes hold the projected product type position during 2026?
• How does gastroenterology influence platform and accessory demand across healthcare facilities?
• Why do hospitals account for the projected end user position during 2026?
• How do country growth rates differ across the USA, UK, Germany, Japan, and South Korea?
• Which companies provide imaging platforms, therapeutic devices, or robotic endoscopy systems?
• What limits adoption across reusable scopes and connected imaging platforms?
• How should healthcare executives compare imaging performance with service and workflow requirements?